{"id":"aricept-tab","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2171854","moleculeType":"Small molecule","molecularWeight":"417.95"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the enzyme acetylcholinesterase, donepezil increases the levels of acetylcholine in the brain, which is a neurotransmitter that plays a key role in memory and learning. This can help to slow down the progression of Alzheimer's disease symptoms and improve cognitive function in patients with mild to moderate dementia.","oneSentence":"Aricept (donepezil) is a cholinesterase inhibitor that works by increasing the concentration of acetylcholine in the brain, which helps to improve cognitive function in patients with Alzheimer's disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:15.925Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease"},{"name":"Vascular dementia"}]},"trialDetails":[{"nctId":"NCT06903910","phase":"PHASE2","title":"Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2024-11-01","conditions":"Parkinson Disease","enrollment":6},{"nctId":"NCT03810794","phase":"NA","title":"Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease","status":"RECRUITING","sponsor":"Jian Pei,MD","startDate":"2019-03-01","conditions":"Alzheimer Disease, Cognitive Impairment","enrollment":180},{"nctId":"NCT06285240","phase":"PHASE1","title":"Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-03-28","conditions":"Alzheimer's Disease","enrollment":28},{"nctId":"NCT05564169","phase":"PHASE3","title":"Masitinib in Patients With Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"AB Science","startDate":"2026-06","conditions":"Alzheimer Disease","enrollment":600},{"nctId":"NCT06041789","phase":"PHASE2","title":"Effect of Acetylcholinesterase Inhibitors on Bone Metabolism","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-02-03","conditions":"Osteoporosis","enrollment":45},{"nctId":"NCT07066826","phase":"PHASE2, PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type","status":"NOT_YET_RECRUITING","sponsor":"Wanbangde Pharmaceutical Group Co., LTD","startDate":"2025-08-01","conditions":"Alzheimer Dementia","enrollment":720},{"nctId":"NCT03740178","phase":"PHASE1","title":"Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-09-27","conditions":"Alzheimer's Disease, Mild Cognitive Impairment","enrollment":""},{"nctId":"NCT06828289","phase":"","title":"Rivastigmine Mini-Tablet for Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-02-28","conditions":"Alzheimer's Disease","enrollment":1000},{"nctId":"NCT06774261","phase":"PHASE1","title":"Phenserine on the Alzheimer's Treatment Horizon, Study 1","status":"NOT_YET_RECRUITING","sponsor":"Helse Stavanger HF","startDate":"2025-02-01","conditions":"Alzheimer Disease, Mild Cognitive Impairment","enrollment":16},{"nctId":"NCT05345509","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventage Lab., Inc.","startDate":"2023-04-01","conditions":"Alzheimer Disease","enrollment":62},{"nctId":"NCT01406145","phase":"PHASE1","title":"A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-06-16","conditions":"Alzheimer's Disease","enrollment":60},{"nctId":"NCT04617782","phase":"PHASE1","title":"Pharmacokinetic Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers","status":"COMPLETED","sponsor":"Corium, Inc.","startDate":"2020-12-08","conditions":"Healthy Subjects","enrollment":60},{"nctId":"NCT04308304","phase":"PHASE1","title":"MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-16","conditions":"Alzheimer's Disease","enrollment":27},{"nctId":"NCT02626572","phase":"PHASE2","title":"Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2015-02","conditions":"Alzheimer's Disease","enrollment":500},{"nctId":"NCT06393413","phase":"EARLY_PHASE1","title":"To Explore the Therapeutic Potential of Jiedu Yizhi Formula for Alzheimer 's Disease","status":"COMPLETED","sponsor":"Changchun University of Chinese Medicine","startDate":"2022-12-01","conditions":"Ensure the Legality and Compliance of the Testing Process","enrollment":62},{"nctId":"NCT06127368","phase":"PHASE1","title":"Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics From Single Dose of Intramuscular (IM) and Subcutaneous (SC) Donepezil (GB-5001) Injections Versus Donepezil Oral Tablet (Aricept®) in Healthy Male Volunteers","status":"UNKNOWN","sponsor":"G2GBio, Inc.","startDate":"2024-01-03","conditions":"Alzheimer Disease","enrollment":56},{"nctId":"NCT04507438","phase":"PHASE2","title":"The Effect of Donepezil on Glycemic Control in Type II Diabetics","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2019-07-12","conditions":"Diabetes Mellitus, Type 2","enrollment":7},{"nctId":"NCT01872598","phase":"PHASE3","title":"Masitinib in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"AB Science","startDate":"2012-01","conditions":"Alzheimer Disease","enrollment":721},{"nctId":"NCT02822573","phase":"PHASE3","title":"Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-05-30","conditions":"Cognitive Dysfunction, Memory Impairment","enrollment":276},{"nctId":"NCT05525780","phase":"PHASE1","title":"Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 IM Depot and Aricept® Oral Tablets in Healthy Male Volunteers","status":"COMPLETED","sponsor":"G2GBio, Inc.","startDate":"2022-08-26","conditions":"Alzheimer Disease","enrollment":48},{"nctId":"NCT01278407","phase":"PHASE3","title":"A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2011-02","conditions":"Dementia With Lewy Bodies (DLB)","enrollment":142},{"nctId":"NCT02580305","phase":"PHASE2","title":"SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study","status":"COMPLETED","sponsor":"Suven Life Sciences Limited","startDate":"2015-09","conditions":"Alzheimer's Disease","enrollment":564},{"nctId":"NCT04505670","phase":"PHASE2","title":"The Effect of Donepezil on Wound Healing","status":"UNKNOWN","sponsor":"University of Maryland, Baltimore","startDate":"2020-08-30","conditions":"Wound Heal","enrollment":20},{"nctId":"NCT05811000","phase":"PHASE2, PHASE3","title":"A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease","status":"UNKNOWN","sponsor":"Mediforum Ltd., Co.","startDate":"2020-11-27","conditions":"Mild Alzheimer Disease","enrollment":312},{"nctId":"NCT05127746","phase":"PHASE1","title":"Phase 1 Clinical Trial of DA-5207 in Healthy Adults","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2021-11-25","conditions":"Healthy","enrollment":51},{"nctId":"NCT05804279","phase":"PHASE1","title":"Pharmacokinetics of BPDO-1603 or BPDO-16031 and BPDO-16033 Administration in Healthy Adults","status":"COMPLETED","sponsor":"Hyundai Pharm","startDate":"2022-12-28","conditions":"Healthy","enrollment":24},{"nctId":"NCT05641480","phase":"NA","title":"Technical R&D and Demonstration of Intelligent Medical Care in Alzheimer's Disease's Management","status":"UNKNOWN","sponsor":"Shaanxi Hospital of Traditional Chinese Medicine","startDate":"2022-06-03","conditions":"Alzheimer Disease, Subjective Cognitive Decline, Mild Cognitive Impairment","enrollment":150},{"nctId":"NCT00688376","phase":"PHASE3","title":"Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-07-02","conditions":"Attention Impairment","enrollment":72},{"nctId":"NCT00477659","phase":"PHASE4","title":"Neural Correlates In Mild Alzheimer's Disease","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2007-07-23","conditions":"Alzheimer's Disease","enrollment":14},{"nctId":"NCT00369785","phase":"PHASE3","title":"Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2008-02","conditions":"Brain Tumors, Metastatic Disease","enrollment":198},{"nctId":"NCT05003063","phase":"EARLY_PHASE1","title":"Effects of Acetylcholine and Attention on Visual Spatial Representations in the Brain","status":"COMPLETED","sponsor":"University of California, Berkeley","startDate":"2021-02-04","conditions":"Visual Perception, Attention, Information Processing","enrollment":12},{"nctId":"NCT01584076","phase":"PHASE1","title":"Treatment of Residual Amblyopia With Donepezil","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2012-08","conditions":"Amblyopia","enrollment":18},{"nctId":"NCT04479865","phase":"PHASE1","title":"Phase 1 Clinical Trial to Evaluate the Safety, PK and PD of DA-5207 TDS in Healthy Adults","status":"UNKNOWN","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-07-28","conditions":"Healthy","enrollment":49},{"nctId":"NCT03905096","phase":"PHASE1","title":"A Study in Healthy Men and Women to Test Which Effects Donepezil and BI 425809 Have on Each Other","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-04-12","conditions":"Healthy","enrollment":32},{"nctId":"NCT03197740","phase":"PHASE3","title":"A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Icure Pharmaceutical Inc.","startDate":"2017-10-12","conditions":"Alzheimer Disease","enrollment":399},{"nctId":"NCT03441516","phase":"PHASE4","title":"Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia","status":"UNKNOWN","sponsor":"Yuhan Corporation","startDate":"2018-04-19","conditions":"Alzheimer's Disease","enrollment":79},{"nctId":"NCT04134416","phase":"PHASE3","title":"Brain Correlates of Multimodal Rehabilitation in Chronic Post-stroke Aphasia","status":"COMPLETED","sponsor":"University of Malaga","startDate":"2019-01-08","conditions":"Aphasia, Stroke","enrollment":20},{"nctId":"NCT03932916","phase":"PHASE1","title":"Safety and Pharmacokinetic of Donepezil Pamoate in Healthy Subjects","status":"COMPLETED","sponsor":"Shanghai Synergy Pharmaceutical Sciences Co., Ltd.","startDate":"2019-07-02","conditions":"AD","enrollment":38},{"nctId":"NCT02586909","phase":"PHASE3","title":"12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension","status":"TERMINATED","sponsor":"Axovant Sciences Ltd.","startDate":"2016-04-26","conditions":"Alzheimer's Disease","enrollment":1099},{"nctId":"NCT02406261","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-04-30","conditions":"Healthy","enrollment":82},{"nctId":"NCT03283059","phase":"PHASE3","title":"Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2017-08-16","conditions":"Alzheimer Disease","enrollment":600},{"nctId":"NCT03090516","phase":"PHASE2, PHASE3","title":"Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-08-10","conditions":"Alzheimer's","enrollment":240},{"nctId":"NCT02918266","phase":"PHASE1","title":"TAK-071 Scopolamine-Induced Cognitive Impairment Study","status":"TERMINATED","sponsor":"Takeda","startDate":"2016-11-21","conditions":"Healthy Volunteers","enrollment":18},{"nctId":"NCT02769065","phase":"PHASE1","title":"Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants","status":"TERMINATED","sponsor":"Takeda","startDate":"2016-05-05","conditions":"Alzheimer Disease, Healthy Volunteers","enrollment":179},{"nctId":"NCT02345213","phase":"PHASE4","title":"A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2015-03-01","conditions":"Dementia, Lewy Body, Lewy Body Disease","enrollment":160},{"nctId":"NCT02585934","phase":"PHASE3","title":"Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study","status":"COMPLETED","sponsor":"Axovant Sciences Ltd.","startDate":"2015-10","conditions":"Alzheimer's Disease","enrollment":1315},{"nctId":"NCT01213355","phase":"PHASE1","title":"Scopolamine Challenge Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-04","conditions":"Healthy","enrollment":38},{"nctId":"NCT00874939","phase":"PHASE1","title":"A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-06","conditions":"Alzheimer's Disease, Dementia","enrollment":4},{"nctId":"NCT00571064","phase":"PHASE4","title":"The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-01","conditions":"Mild to Severe Alzheimer's Disease","enrollment":97},{"nctId":"NCT02079246","phase":"PHASE3","title":"Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-04-07","conditions":"Alzheimer's Disease","enrollment":1463},{"nctId":"NCT03259958","phase":"PHASE1","title":"A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®","status":"COMPLETED","sponsor":"Corium, Inc.","startDate":"2017-10-30","conditions":"Alzheimer's Disease","enrollment":86},{"nctId":"NCT02968719","phase":"PHASE1","title":"A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®","status":"COMPLETED","sponsor":"Corium, Inc.","startDate":"2016-11","conditions":"Alzheimer Disease","enrollment":107},{"nctId":"NCT03569579","phase":"PHASE1","title":"CKD-355 Drug-drug Interaction Study (CKD-355 DDI P1)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-04-16","conditions":"Central Nervous System Diseases","enrollment":20},{"nctId":"NCT02006641","phase":"PHASE3","title":"Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-02","conditions":"Alzheimer's Disease","enrollment":858},{"nctId":"NCT00408525","phase":"PHASE1","title":"Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2006-12","conditions":"Alzheimer's Disease","enrollment":41},{"nctId":"NCT00348309","phase":"NA","title":"Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-07-06","conditions":"Alzheimer's Disease","enrollment":1496},{"nctId":"NCT01658228","phase":"PHASE4","title":"Combination Treatment Study for Memory Impairment and Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2011-09","conditions":"Depression, Mild Cognitive Impairment","enrollment":86},{"nctId":"NCT01955161","phase":"PHASE3","title":"Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-10","conditions":"Alzheimer's Disease","enrollment":933},{"nctId":"NCT00428090","phase":"PHASE3","title":"Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-27","conditions":"Alzheimer's Disease","enrollment":862},{"nctId":"NCT01194336","phase":"","title":"Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2012-02","conditions":"Biomarkers, Pharmacological","enrollment":84},{"nctId":"NCT01404169","phase":"PHASE3","title":"A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2011-09","conditions":"Alzheimer's Type Dementia","enrollment":260},{"nctId":"NCT02051335","phase":"PHASE1","title":"Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-01","conditions":"Memory Impairment, Alzheimer's Disease","enrollment":27},{"nctId":"NCT01098383","phase":"PHASE4","title":"Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2010-03","conditions":"Autism","enrollment":84},{"nctId":"NCT00352664","phase":"PHASE3","title":"The Effect of Donepezil on Sedation and Other Symptoms","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-11","conditions":"Advanced Cancer","enrollment":27},{"nctId":"NCT01822951","phase":"PHASE4","title":"Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)","status":"WITHDRAWN","sponsor":"Ever Neuro Pharma GmbH","startDate":"","conditions":"Alzheimer Disease","enrollment":""},{"nctId":"NCT02570581","phase":"PHASE1","title":"MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2014-06","conditions":"Healthy","enrollment":16},{"nctId":"NCT01487395","phase":"PHASE1","title":"Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2011-12","conditions":"Alzheimer Disease, Battery","enrollment":30},{"nctId":"NCT00630851","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-10","conditions":"Alzheimer Disease","enrollment":249},{"nctId":"NCT01461174","phase":"PHASE1","title":"Effects of Donepezil and Memantine on Cognitive Functions After a Sleep Deprivation Challenge in Healthy Volunteers","status":"COMPLETED","sponsor":"Qualissima","startDate":"2011-11","conditions":"Healthy","enrollment":36},{"nctId":"NCT01451749","phase":"PHASE3","title":"Efficacy and Safety Study of Shenwu Capsule","status":"COMPLETED","sponsor":"North China Pharmaceutical Group Corporation","startDate":"2008-09","conditions":"Mild Cognitive Impairment","enrollment":324},{"nctId":"NCT00598650","phase":"PHASE2","title":"A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2008-02","conditions":"Dementia With Lewy Bodies (DLB)","enrollment":160},{"nctId":"NCT01255046","phase":"PHASE2","title":"Study of STA-1 as an Add-on Treatment to Donepezil","status":"UNKNOWN","sponsor":"Sinphar Pharmaceutical Co., Ltd","startDate":"2015-12","conditions":"Alzheimer Disease","enrollment":136},{"nctId":"NCT00702780","phase":"NA","title":"Progression Delaying Effect of Escitalopram in Alzheimer's Disease","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2008-11","conditions":"Alzheimer's Disease","enrollment":74},{"nctId":"NCT01903824","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-08","conditions":"Cognitive Impairment","enrollment":40},{"nctId":"NCT01082965","phase":"NA","title":"Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-07","conditions":"Alzheimer's Disease","enrollment":18},{"nctId":"NCT01419366","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceutical Limited's Donepezil Hydrochloride Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT01923259","phase":"PHASE1","title":"Bioavailability Study of Donepezil Hydrochloride Tablets 23 mg Under Fed Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2010-10","conditions":"Healthy","enrollment":94},{"nctId":"NCT01923558","phase":"PHASE1","title":"Bioavailability Study of Donepezil Hydrochloride Tablets 23 mg Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2010-10","conditions":"Healthy","enrollment":76},{"nctId":"NCT00543855","phase":"PHASE2","title":"A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2007-11","conditions":"Dementia With Lewy Bodies (DLB)","enrollment":167},{"nctId":"NCT00895895","phase":"PHASE2","title":"Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-05","conditions":"Alzheimer Disease","enrollment":526},{"nctId":"NCT01146509","phase":"PHASE2","title":"An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2003-01","conditions":"Migraine Headache","enrollment":89},{"nctId":"NCT00711204","phase":"PHASE4","title":"Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease","status":"WITHDRAWN","sponsor":"Eisai Inc.","startDate":"2008-01","conditions":"Severe Alzheimer's Disease","enrollment":""},{"nctId":"NCT01276067","phase":"PHASE1","title":"Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2009-10","conditions":"Healthy","enrollment":32},{"nctId":"NCT01276080","phase":"PHASE1","title":"Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2009-10","conditions":"Healthy","enrollment":36},{"nctId":"NCT01506752","phase":"PHASE1","title":"A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2011-07","conditions":"Healthy Adult","enrollment":20},{"nctId":"NCT00842816","phase":"PHASE2","title":"Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease","status":"COMPLETED","sponsor":"Sonexa Therapeutics, Inc.","startDate":"2009-02","conditions":"Alzheimer's Disease","enrollment":210},{"nctId":"NCT01450839","phase":"PHASE1","title":"E2022 Patch Formulation Multiple Dose Study","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2011-09","conditions":"Healthy","enrollment":16},{"nctId":"NCT01506739","phase":"PHASE1","title":"A Bioequivalence Study of Film-coated Tablet and Dry Syrup 1% Form for E2020 in Healthy Japanese Adult Males","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2011-03","conditions":"Healthy Adult","enrollment":12},{"nctId":"NCT01504503","phase":"PHASE1","title":"Bioequivalence Study for Donepezil Hydrochloride 10 mg Tablets Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2009-10","conditions":"Healthy","enrollment":26},{"nctId":"NCT01504516","phase":"PHASE1","title":"Bioequivalence Study for Donepezil Hydrochloride Tablets 10 mg Under Fed Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2009-10","conditions":"Healthy","enrollment":25},{"nctId":"NCT01345864","phase":"PHASE1","title":"Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults","status":"TERMINATED","sponsor":"Pfizer","startDate":"2011-05","conditions":"Healthy","enrollment":88},{"nctId":"NCT01439230","phase":"PHASE1","title":"Donepezil 10 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2007-06","conditions":"Healthy","enrollment":36},{"nctId":"NCT01439243","phase":"PHASE1","title":"Donepezil 10 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2007-06","conditions":"Healthy","enrollment":26},{"nctId":"NCT01419340","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceutical Limited's Donepezil Hydrochloride Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT01089582","phase":"","title":"Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11","conditions":"Alzheimer Disease","enrollment":628},{"nctId":"NCT00959881","phase":"PHASE1","title":"Study Evaluating The Coadministration of Begacestat And Donepezil","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2009-08","conditions":"Healthy Subjects","enrollment":47},{"nctId":"NCT00293176","phase":"PHASE4","title":"The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2003-12","conditions":"Memory Loss","enrollment":821},{"nctId":"NCT00889603","phase":"","title":"Non-Interventional Study With Aricept® Evess","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-05","conditions":"Alzheimer's Disease, Vascular Dementia","enrollment":370},{"nctId":"NCT01260922","phase":"PHASE1","title":"10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2006-04","conditions":"Healthy","enrollment":26},{"nctId":"NCT01260948","phase":"PHASE1","title":"10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2006-04","conditions":"Healthy","enrollment":26}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DEATH"},{"count":1,"reaction":"OFF LABEL USE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"aricept Tab","genericName":"aricept Tab","companyName":"Icure Pharmaceutical Inc.","companyId":"icure-pharmaceutical-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aricept (donepezil) is a cholinesterase inhibitor that works by increasing the concentration of acetylcholine in the brain, which helps to improve cognitive function in patients with Alzheimer's disease. Used for Alzheimer's disease, Vascular dementia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}